In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development

Executive Summary

The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging. Locust Walk Partners surveyed senior business development executives to find the keys to executing mutually satisfying deals.

You may also be interested in...

Your First Drug's Approved and Launched...Now What?

FDA new drug approvals are making a comeback, and a group of biopharma first-timers are leading the way. To understand the challenges they face in the transition from discovery to commercialization, IN VIVO looked at 50 companies spanning the past 10 years. Finally reaching the US market might be a biotech's defining moment, but for those who build to last, there could be more rewards beyond that first approval.

Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model

In an era in which biotechs struggle to get financing and Big Pharma is hungry for new drugs but typically favors deals that delay rewards, Plexxikon Inc. appears to have been dealt a top R&D hand and played its cards exceedingly well. Its strategy has culminated in one of the priciest private buyouts in recent history, its $805 million up-front acquisition by Japan’s Daiichi Sankyo Co. Ltd.

Reimbursement: The New Biopharma Investment Hurdle

With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.

Related Content

Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts